Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Ultrasound show unexpected effects on motor neuron disease

Published on: 05/09/2024 Reading time: 1 min
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.

Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain Institute, Séverine Boillée's team, in collaboration with Professor Alexandre Carpentier from the neurosurgery department at the Pitié-Salpêtrière hospital and the startup CarThera, have demonstrated that this technique can also be applied to the blood–spinal cord barrier. And in motor neuron disease, ultrasound treatment alone could be a promising avenue! These pioneering results, obtained in mice, are published in eBioMedicine.

Most drugs cannot cross the blood-brain barrier, the natural border that protects the central nervous system from potentially toxic substances circulating in the bloodstream. But they are also held in check by a lesser-known adversary: the blood-spinal cord barrier—made up of small blood vessels—which plays a similar role around the spinal cord.

These natural barriers are a major obstacle to the development and evaluation of new drugs in neurology. In amyotrophic lateral sclerosis (ALS), or motor neuron disease, we constantly seek new techniques to help therapeutic molecules reach the motor neurons.

Séverine BOILLÉE Researcher at Paris Brain Institute, (Inserm)

Indeed, amyotrophic lateral sclerosis causes the progressive degeneration of motor neurons, the cells that control the body's voluntary muscles. Located in the cerebral cortex and the anterior part of the spinal cord, their destruction causes progressive paralysis of the limbs and the muscles that control breathing and swallowing.

Opening a pathway to motor neurons

Previous research* has shown that it is possible to temporarily open the blood-brain barrier by injecting microbubbles into the bloodstream: these vibrate under the effect of low-intensity ultrasound, inducing mechanical stress on the vessel walls. The blood-brain barrier is then disrupted, allowing therapeutic molecules to pass into the brain for a few hours.

Séverine Boillée and her colleagues, in collaboration with Prof. Alexandre Carpentier (AP-HP, Sorbonne University), are the first to precisely evaluate the efficacy and safety of this technique in motor neuron disease, this time targeting the spinal cord. Their aim? Administering to ALS mice a treatment that has already demonstrated its potential in animals—the growth hormone IGF1—as close as possible to the motor neurons.

To facilitate the therapeutic molecule's action, the researchers used pulsed ultrasound once a week for five weeks in the animals' lumbar region. Their results are encouraging: a single session resulted in a high concentration of IGF1 in the spinal cord. After five weeks, the animals treated with ultrasound had a longer life expectancy than those who had received growth hormone alone, or a placebo.

Un transducteur à ultrasons de 1 MHz a été positionné de manière à cibler la moelle épinière lombaire de la souris. Les ultrasons pulsés ont été administrés pendant 150s, en même temps que les microbulles. Crédit : Institut du Cerveau (CC BY 4.0).
A 1 MHz ultrasound transducer was positioned to target the mouse's lumbar spinal cord. Pulsed ultrasounds were administered for 150 seconds at the same time as the microbubbles. Credit: Paris Brain Institute (CC BY 4.0).

An unexpected phenomenon

We also observed a surprising phenomenon. The mice that received ultrasound without medication lived longer than the controls,” explains Séverine Boillée. “In other words, ultrasound alone was effective in slowing the progression of the disease, whereas IGF1 showed no benefit.”

What if pulsed ultrasound could be used as a therapeutic tool in amyotrophic lateral sclerosis? Of course, further studies will be needed to understand the mechanism that enabled the mice to live longer. But the team is already on to something: ultrasound may have affected immune cells.

The tools we need to use ultrasound in the human spinal cord must now be developed,” adds the researcher. However, the clinical tools that allow us to intervene in the brain are already there: Prof. Alexandre Carpentier, Prof. Gaëlle Bruneteau (AP-HP), a neurologist at the ALS Centre in Paris, and the start-up CarThera will shortly be launching the SonoSLA therapeutic trial; it will assess the absence of ultrasound toxicity and the tolerance of the device in ALS patients, followed by its efficacy on symptoms. “This strategy could open up real therapeutic prospects for patients,” concludes Séverine Boillée.

 

Funding

This study was funded by the Laboratoire de Recherche en Technologies Chirurgicales Avancées (LRTCA), the Foundation for Medical Research (FRM), the French Society of Neurosurgery (SFNC), the Fonds d’Études et de Recherche du Corps Médical (FERCM) of the Paris hospitals, l’Aide à la Recherche des Maladies du Cerveau (ARMC), SLA Fondation Recherche (SLAFR), and the Investments for the Future program.

Declaration of interests

Alexandre Carpentier is a consultant for the university start-up CarThera, which he founded. He has interests in the company and has filed patents held by Sorbonne University relating to the results presented in the article.

Sources

Montero, A. S. et al. Effects of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an amyotrophic lateral sclerosis mouse model. eBioMedicine, Juillet 2024. DOI : 10.1016/j.ebiom.2024.105235

Autres références (*)

Carpentier, A. et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nature Communications, Février 2024. DOI : 10.1038/s41467-024-45818-7 

Sonabend, A. M. et al. Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. The Lancet Oncology, Mai 2023. DOI : 10.1016/S1470-2045(23)00112-2

Carpentier, A. et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Science Translational Medicine, Juin 2016. DOI : 10.1126/scitranslmed.aaf60

Bannière de l'équipe Causes de la SLA et mécanismes de la dégénérescence motoneuronale
Team
DecodALS: ALS causes and mechanisms of motor neuron degeneration

The team led by Séverine BOILLEE is interested in the mechanisms that induce motoneuron degeneration in ALS and that may result from a deleterious interaction between these neurons and microglial and macrophage cells (immune system cells).

Read more

Our news on the subject

Le développement du cerveau a une part d’aléatoire
The stochastic aspect of brain development
Although every person’s personality is the result of genetic and environmental factors, these are not the only factors at play. Bassem Hassan and his team at Paris Brain Institute have discovered that, in fruit flies (drosophila), individuality also...
05.12.2025 Research, science & health
Analyse MERSCOPE
New treatment pathways for brain malformation-linked focal epilepsy?
A study by Stéphanie Baulac’s team has revealed somatic mutations in different cell types in patients with type 2 focal cortical dysplasia. This disease causes drug-resistant epileptic seizures, for which the main treatment option is currently...
05.12.2025 Research, science & health
Un iceberg
The ICEBERG cohort, 10 years of collective scientific and medical mobilization
The ICEBERG cohort, initiated 10 years ago, is interested in studying factors predictive of the onset and progression of Parkinson’s disease.
05.15.2025 Research, science & health
La huntingtine est une protéine indispensable au développement embryonnaire, à la formation et au maintien du tissu cérébral.
Huntington's Disease: The Energy Hypothesis Gets Traction
Huntington's disease, a rare hereditary neurological disorder, is associated with an energy deficit that precedes the onset of symptoms and is closely linked to their progression. At Paris Brain Institute, Fanny Mochel and her colleagues are testing...
02.11.2025 Research, science & health
À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Stéphanie Debette
Professor Stéphanie Debette takes the helm of Paris Brain Institute
Appointed Executive Director of Paris Brain Institute for a five-year term, Professor Stéphanie Debette took up her new position on January 1, 2025. She succeeds Professor Alexis Brice, who has served as Executive Director since 2012.
01.07.2025 Institutional
See all our news